Résumé
OBJETIVOS: Determinar o efeito do tratamento da DRGE no controle clinico e funcional respiratório em indivíduos asmáticos e avaliar as características clinicas deste grupo de pacientes. MÉTODOS: Pacientes com asma portadores de DRGE patológico documentado por pHmetria de 24 h foram avaliados por meio de questionários sobre sintomas respiratórios, digestivos, de qualidade de vida além de manometria esofágica, espirometria e pico de fluxo expiratório antes e após o estudo. Quarenta e nove indivíduos que apresentavam DRGE patológico na pHmetria esofágica de 24 h foram selecionados e participaram de ensaio clínico terapêutico com pantoprazol (40 mg/dia) controlado com placebo, randomizado, duplo-cego, paralelo por 12 semanas consecutivas. RESULTADOS: Quarenta e quatro indivíduos completaram o estudo (n = 22 cada grupo). Houve melhora significativa no escore de sintomas respiratórios e na qualidade de vida somente no grupo que utilizou pantoprazol (p = 0,01 e p = 0,001, respectivamente). Os parâmetros funcionais respiratórios não se modificaram com os diferentes tratamentos. CONCLUSÕES: Neste estudo, o tratamento efetivo do RGE melhorou a qualidade de vida, determinou diminuição dos sintomas em asma de maneira significativa no grupo que utilizou medicamento, contudo sem alterar os parâmetros funcionais.
OBJECTIVES: To determine the effect that the treatment of GERD has on the clinical management, as well as the respiratory function, of patients with asthma and to evaluate the clinical characteristics of this group of patients. METHODS: Patients with asthma and concomitant GERD, documented using 24 h pH-metry, were evaluated by means of quality of life questionnaires, as well as questionnaires related to respiratory and digestive symptoms. In addition, esophageal manometry, spirometry and the determination of peak expiratory flow were also performed prior to and after the study. Forty-nine individuals who were diagnosed with GERD by means of 24 h esophageal pH-metry were selected and participated in a clinical randomized double-blind placebo-controlled study, involving the administration of 40 mg/day of pantoprazol for 12 consecutive weeks. RESULTS: Forty-four individuals completed the study (n = 22 per group). There was significant improvement in the scores for respiratory symptoms and quality of life only in the group that received pantoprazol (p = 0.01 and p = 0.001, respectively). No respiratory function parameters changed in either group. CONCLUSIONS: In this study, the effective treatment of GERD improved patient quality of life, and the symptoms of asthma significantly decreased in the group that received the medication. There were no changes in pulmonary function parameters.